Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NSI 566

Drug Profile

NSI 566

Alternative Names: hCNS-SC - Palisade Bio; HuCNS-SC - Palisade Bio; Neural Stem Cells - Palisade Bio; NSI-566; NSI-566RSC

Latest Information Update: 28 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neuralstem
  • Developer Emory University; HK inno.N; Neuralstem China; Palisade Bio; Seneca Biopharma; University of California, San Diego; University of Freiburg
  • Class Neural stem cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Neurogenesis stimulants; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Paralysis
  • Phase II Amyotrophic lateral sclerosis
  • No development reported Spinal cord injuries
  • Discontinued Alzheimer's disease; Brain injuries; Cerebral palsy; Cognition disorders; Diabetic neuropathies; Huntington's disease; Lysosomal storage diseases; Multiple sclerosis; Optic neuritis; Paraplegia; Parkinson's disease

Most Recent Events

  • 28 Jun 2023 No recent reports of development identified for phase-I development in Spinal-cord-injuries in USA (Intraspinal, Injection)
  • 27 Apr 2021 Leading BioSciences has merged with Seneca Biopharma to form Palisade Bio
  • 27 Apr 2021 Leading BioSciences has merged with Seneca Biopharma to form Palisade Bio
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top